Dispatch Biotherapeutics, Inc.

Dispatch Biotherapeutics, Inc. is a Philadelphia-based company focused on developing immunotherapy solutions to effectively treat solid tumors, leveraging advanced engineering techniques to enhance immune response against cancer. Founded in 2022, Dispatch Biotherapeutics specializes in providing innovative treatments for solid tumors. The company operates out of Philadelphia, US, and has executed 2 key deals since its inception.

Details about the founder and further history are not disclosed. Dispatch Biotherapeutics specializes in developing innovative immunotherapy solutions aimed at treating solid tumors, an area where traditional cancer treatments have shown limited effectiveness. The core offering revolves around their Flare platform, designed to address the challenges of targeting and resistance commonly encountered in various solid tumor types. This first-in-class approach leverages advanced engineering methods to enhance the immune response against tumors, ultimately aiming for curative outcomes.

The target market for these products includes healthcare providers and institutions involved in oncology, particularly in regions known for advanced cancer treatment infrastructure, such as North America and Europe. By focusing on the complexities of solid tumors, Dispatch Biotherapeutics seeks to serve a diverse client base, including hospitals, research centers, and pharmaceutical partners. The revenue generation model for Dispatch Biotherapeutics is primarily based on partnerships and collaborations within the pharmaceutical and biotechnology sectors. Transactions typically occur through strategic alliances with healthcare institutions and research organizations, allowing for the distribution of their immunotherapy solutions.

These partnerships may involve licensing agreements or shared development costs, facilitating access to their proprietary Flare platform. The company’s revenue is further supported by potential milestone payments and royalties linked to the successful commercialization of their products. Although specific pricing plans and individual product costs are not disclosed, the structure suggests a B2B approach, where revenue is derived from direct interactions with healthcare providers and research entities focused on advancing cancer treatment. Dispatch Biotherapeutics is focused on expanding its product portfolio and market reach.

The company is actively working on new immunotherapy products aimed at providing innovative solutions for solid tumors. The firm intends to expand into European and Asian markets by 2025, targeting regions with robust oncology infrastructure. In July 2025, Dispatch Biotherapeutics, Inc. raised USD 100 million in series A funding co-led by new investors ARCH Venture Partners and Parker Institute for Cancer Immunotherapy, with participation from other new investors Alexandria Venture Investments, Bristol-Myers Squibb Company, Stanford University, and University of Pennsylvania Endowment.